Adjuvant vaccination with allogenic dendritic cells significantly prolongs overall survival in high-grade gliomas: results of a phase ii trial

HIGHLIGHTS

  • who: Guilherme Lepski and colleagues from the Laboratory of Experimental Surgery (LIM26), Hospital das Clu00ednicas, Medical School, Universidade Su00e3o Paulo, Su00e3o Paulo, Brazil have published the article: Adjuvant Vaccination with Allogenic Dendritic Cells Significantly Prolongs Overall Survival in High-Grade Gliomas: Results of a Phase II Trial, in the Journal: Cancers 2023, 15, 1239. of /2023/
  • what: The authors report the results of a phase I/II prospective non-controlled clinical trial with 37 patients harboring glioblastoma or grade 4 astrocytomas.

SUMMARY

    The current DC-vaccination trial included 37 patients with . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?